Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05181618 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis

Name: A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis — clinical trial record (NCT05181618)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: Beyond ABR

StatusActive, Not Recruiting

PhasePhase 4

SponsorHoffmann-La Roche

Started2022-06-20

View on ClinicalTrials.gov ↗

Study MO42623 is a Phase IV, multicenter, open-label, three cohort study designed to evaluate the impact of emicizumab prophylaxis on overall health, physical activity, and joint outcomes in participants aged ≥13 and \<70 years with severe hemophilia A without factor VIII (FVIII) inhibitors or moderate hemophilia A without FVIII inhibitors who are receiving FVIII prophylaxis and who will start emicizumab treatment as part of this study.

Amendment history 2 changes detected by DataLookout

2026-07-28

Primary completion pushed: 2026-12-04 → 2027-11-30

2026-07-28

Completion pushed: 2027-05-21 → 2027-11-30

Trial Details

NCT Number	NCT05181618
Lead Sponsor	Hoffmann-La Roche
Conditions	Severe Hemophilia A, Moderate Hemophilia A
Enrollment	136 participants
Start Date	2022-06-20
Primary Completion	2027-11-30 (estimated)
Study Completion	2027-11-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-27